Business Context and Reporting Period
This Form 6-K filing by Bioblast Pharma Ltd. (also referenced as Enlivex Ltd. in metadata) covers the month of March 2019, with the report dated March 6, 2019. The filing serves to announce the effectiveness of an eight-to-one reverse split of the company's share capital and a corresponding amendment to its articles of association.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a corporate action announcement and does not contain financial performance data.
Material Changes
The primary material change reported is the implementation of an eight-to-one reverse stock split. This action reduces the number of outstanding shares while proportionally increasing the par value per share, with no change to the total share capital value.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, specific risks, or contingencies beyond the procedural details of the reverse split. No unusual items were reported in this document.
Investor Verification Checklist
- Verify the post-split share count and adjusted trading price on the relevant exchange.
- Confirm the updated par value per share as reflected in the amended articles of association.
- Review subsequent filings for any financial impact or operational updates related to the capital restructuring.